Cyclopamine is a Hedgehog (Hh) pathway antagonist with an IC50 of 46 nM in the Hh cell assay, it can increase levels of p27, and decreases both expression of IGF-II and activation of Akt in PC-3 prostate cancer cells. Cyclopamine as a novel, potent inhibitor of human breast cancer proliferation and estrogen responsiveness that could potentially be developed into a promising therapeutic agent for the treatment of breast cancer. Cyclopamine also can suppress the growth of leukemia and lymphoma cells. Cyclopamine is a member of piperidines. It has a role as a glioma-associated oncogene inhibitor.

27-Hydroxycholesterol is a selective estrogen receptor modulator and an agonist of the liver X receptor, it may negatively modulate cognitive effects and cholesterol metabolism in the brain. 27-Hydroxycholesterol can enhance cell release of IL-8, IL-1β, and TNF-α and to upregulate matrix metalloproteinase-9 (MMP-9) via TLR4/NF-κB-dependent pathway; it also can reduce hepatic inflammation in hyperlipidemic mice. (25R)-cholest-5-ene-3beta,26-diol is a 26-hydroxycholesterol in which the 25-position has R-configuration. It has a role as a neuroprotective agent, an apoptosis inducer, a mouse metabolite and a human metabolite. It is functionally related to a cholesterol.

Chenodeoxycholic acid is a dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively. It has a role as a mouse metabolite and a human metabolite. It is a C24-steroid, a dihydroxy-5beta-cholanic acid and a bile acid. It is a conjugate acid of a chenodeoxycholate. Chenodeoxycholic acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism. Chenodeoxycholic acid could reverse obesity in cHF-fed mice, mainly in response to the reduction in food intake.